WO2016013352A1 - Procédé de production d'une cellule adipeuse dédifférenciée - Google Patents
Procédé de production d'une cellule adipeuse dédifférenciée Download PDFInfo
- Publication number
- WO2016013352A1 WO2016013352A1 PCT/JP2015/068658 JP2015068658W WO2016013352A1 WO 2016013352 A1 WO2016013352 A1 WO 2016013352A1 JP 2015068658 W JP2015068658 W JP 2015068658W WO 2016013352 A1 WO2016013352 A1 WO 2016013352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adipocytes
- dedifferentiated
- cells
- less
- mature
- Prior art date
Links
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 127
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 102000029816 Collagenase Human genes 0.000 claims abstract description 35
- 108060005980 Collagenase Proteins 0.000 claims abstract description 35
- 229960002424 collagenase Drugs 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 76
- 210000000577 adipose tissue Anatomy 0.000 claims description 20
- 230000004069 differentiation Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 6
- 210000000963 osteoblast Anatomy 0.000 claims description 5
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 210000003098 myoblast Anatomy 0.000 claims description 3
- 239000002609 medium Substances 0.000 description 13
- 230000006698 induction Effects 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 210000000033 corpus adiposum buccae Anatomy 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Definitions
- the present invention relates to a method for producing dedifferentiated fat cells (DFAT cells). More specifically, the present invention relates to a method for isolating mature adipocytes by treating adipose tissue with a specific concentration of collagenase and producing dedifferentiated adipocytes from the mature adipocytes.
- DFAT cells dedifferentiated fat cells
- the present inventors have isolated mature adipocytes from adipose tissue and produced dedifferentiated adipocytes from the mature adipocytes.
- Dedifferentiated adipocytes are cells that have re-acquired pluripotency obtained by spontaneously initiating dedifferentiation of mature adipocytes by culturing isolated mature adipocytes by a ceiling culture method. It is considered useful as a cell source for regenerative medicine.
- it is important to efficiently isolate mature adipocytes from adipose tissue under conditions that do not damage the cells as much as possible. Therefore, the present inventors examined the optimum collagenase concentration in the treatment of adipose tissue for producing a large amount of dedifferentiated adipocytes in the present invention.
- An object is to provide an efficient method for producing dedifferentiated adipocytes.
- the inventors of the present invention have found that the concentration of collagenase conventionally used at a concentration of 0.1 w / v% in the isolation of mature adipocytes from adipose tissue Matured adipocytes can be collected at a efficiency about 3 times higher than the conventional concentration when the concentration is higher than 0.01 w / v% and lower than 0.1 w / v%. Has been found to be able to be produced, and the present invention has been completed.
- the present invention relates to the following (1) to (6) methods for producing dedifferentiated adipocytes.
- a method for producing dedifferentiated adipocytes comprising the following step A.
- A. A step of isolating mature adipocytes by treating adipose tissue with collagenase at a concentration higher than 0.01 w / v% and lower than 0.1 w / v% (2) The concentration of collagenase is 0.02 w / v
- the production method according to (1) wherein the production method is v% or more and 0.05% or less.
- the present invention it becomes possible to collect mature adipocytes with high efficiency without damaging isolated mature adipocytes.
- the cost can be reduced by reducing the amount of collagenase used in the treatment.
- the “method for producing dedifferentiated adipocytes” of the present invention may be any method for producing dedifferentiated adipocytes, including the following step A, and includes other steps useful for efficient production of dedifferentiated adipocytes. It may be included.
- adipose tissue obtained from subcutaneous or internal organs is treated with collagenase at a concentration higher than 0.01 w / v% and lower than 0.1 w / v%.
- the enzyme solution containing mature adipocytes obtained by this collagenase treatment is filtered with a mesh having a pore size of 100 and 150 ⁇ m, and a single fraction consisting of only monocystic adipocytes which are mature adipocytes For example, isolation of mature adipocytes.
- the concentration of collagenase may be higher than 0.01 w / v% and lower than 0.1 w / v%, particularly 0.02 w / v% or more and 0.05% or less. Is preferred.
- the mature adipocytes to be produced may have a normal size of about 60 to 100 ⁇ m, but are preferably less than 60 ⁇ m, particularly preferably less than 40 ⁇ m.
- the “dedifferentiated adipocyte production method” of the present invention may further include the following step B.
- the isolated mature adipocytes are cultured by a ceiling culture method. Can be mentioned.
- the present invention of the present inventors Patent Nos. 5055611 and 5055613 may be referred to.
- the “method for producing mesenchymal cells” of the present invention may be any method for producing mesenchymal cells, including the step of inducing differentiation of dedifferentiated adipocytes obtained by “method for producing dedifferentiated adipocytes”. Other processes useful in the production of mesenchymal cells may be included. “Mesenchymal cells” include osteoblasts, myoblasts, cardiomyocytes, endothelial cells, chondrocytes or adipocytes. In the step of inducing differentiation of dedifferentiated adipocytes, any conventionally known methods such as agents and methods useful for inducing differentiation can be used in accordance with the cells to be differentiated.
- Step A Step of isolating mature adipocytes from adipose tissue 5 g of adipose tissue collected from the buccal fat pad located under the human buccal mucosa is added with collagenase (Type II; SIGMA) and NaHCO 3 -containing Dulbecco's modified Eagle medium (DMEM; SIGMA) And treated with collagenase.
- collagenase Type II; SIGMA
- DMEM Dulbecco's modified Eagle medium
- the collagenase concentration in the medium was 0.02 w / v%, and a comparison was made with a concentration of 0.01 w / v%, 0.10 w / v%, or 0.50 w / v% for comparison.
- the solution was filtered through a nylon mesh to obtain a cell suspension.
- the obtained cell suspension is centrifuged at 700 G for 1 minute, the monocystic fat fraction separated in the upper layer is added to fresh DMEM medium supplemented with 10% FBS, and the centrifugation at 700 G is repeated 3 times for 1 minute.
- mature adipocytes were obtained as monocystic adipocytes.
- Step B Step of obtaining dedifferentiated adipocytes from mature adipocytes
- the monocystic adipocytes obtained by step A are transferred to a tissue culture flask (Falcon, 3107), and are added to a DMEM medium supplemented with 20% FBS, 1% penicillin / streptomycin.
- the flask was completely filled, and it was left to stand in a carbon dioxide culture apparatus adjusted to a gas phase of 37 ° C., 5% CO 2 , 95% air, and cultured for 7 days. After 4 days of culture, most of the cells adhered firmly to the ceiling surface of the flask, and the morphology changed to multivesicular adipocytes having lipid droplets of various sizes around the large lipid droplets.
- the lipid droplets became even smaller, and many cells that changed to a fibroblast-like morphology without any lipid droplets were observed.
- the medium in the flask was replaced with 20% FBS-added DMEM medium, and culturing was continued for 10 days in a carbon dioxide culture apparatus so that the cell adhesion surface was the bottom. The medium was changed every 4 days. Cells without lipid droplets proliferated actively, and after 10 days in culture, the cells in the flask became only fibroblast-like cells and reached confluence.
- This fibroblast-like cell has an active proliferative ability and also has a differentiation ability to redifferentiate into adipocytes having lipid droplets by a differentiation inducer such as DEX, INS, IBMX, etc. It was created as a cell-derived dedifferentiated adipocyte.
- the produced dedifferentiated adipocytes were resuspended in DMEM medium supplemented with 20% FBS so as to be 1 ⁇ 10 4 cells / ml. Thereafter, the cells were seeded in a culture flask for tissue culture (Falcon, 3001) coated with collagen type II, and left in a carbon dioxide culture apparatus adjusted to a gas phase of 37 ° C., 5% CO 2 and 95% air. And cultured. The medium was changed every 4 days. After 8 days of culture, the number of cells was counted when the dedifferentiated adipocytes of the present invention reached confluence (FIGS. 1-3, P1). Thereafter, the second subculture was performed and the number of cells was similarly counted (FIGS. 1 to 3, P2), and then the third subculture was performed and the number of cells was similarly counted (FIGS. 1 to 3). , P3).
- Example 2 Method for producing dedifferentiated adipocytes (2) 1. Comparison of the number of mature adipocytes A collagen tissue treatment was performed on adipose tissue collected from human buccal fat pad in the same manner as in Example 1. After treatment with collagenase at each concentration for 1 hour, extracellular matrix components were removed using a 100 ⁇ m cell strainer (BD FALCON), followed by filtration and low-speed centrifugation to obtain a mature adipocyte fraction. The number of cells contained in 200 ⁇ l of the floating cell fraction at each collagenase concentration was measured using a Coulter Counter (registered trademark) Multisizer 3 (Beckman Coulter, Miami, FL, USA), and the number of mature fat cells collected. Compared. This measurement was performed three times for each concentration.
- BD FALCON 100 ⁇ m cell strainer
- the number of cells contained in 200 ⁇ l of the floating cell fraction at each collagenase concentration was measured using a Coulter Counter (registered trademark) Multisizer 3 (Beckman Co
- the number of mature adipocytes obtained by the above 1 and 2 is shown in FIG.
- mature fat cells having a size in the range of 60 ⁇ m or more and less than 100 ⁇ m were collected in the same number of mature fat cells at any collagenase concentration.
- mature adipocytes with a size of less than 60 ⁇ m can be collected in a significantly larger amount than other concentrations when the collagenase concentration is 0.02 w / v%.
- mature adipocytes having a size of less than 40 ⁇ m can be collected 6 times or more when the collagenase concentration is 0.02 w / v% compared to other concentrations.
- Fluorescent staining The fraction of cells less than 40 ⁇ m or the fraction of cells less than 40 ⁇ m and less than 100 ⁇ m collected in Adipore (Lonza, Walkerslive, MD, USA) positive for lipid droplets (triglycerides) and Hoechst 33342 (Sigma) positive for nuclei -Aldrich, 5 ⁇ g / ml) was stained for 20 minutes and observed with a fluorescence microscope (KEYENCE). As a result, as shown in FIG. 5, both the cell fraction of less than 40 ⁇ m (FIG. 5, A) and the cell fraction of 40 ⁇ m to less than 100 ⁇ m (FIG. 5, B) were stained with triglycerides and nuclei. It was confirmed to be a mature adipocyte.
- the number of mature adipocytes of less than 40 ⁇ m is significantly larger than that of mature adipocytes of 40 ⁇ m or more and less than 100 ⁇ m from the 6th day of the ceiling culture, and dedifferentiated adipocytes are removed. It was confirmed that it differentiated.
- CD13 PE-CD13
- CD44 FITC-CD44
- CD45 FITC-CD45
- CD73 PE-CD73
- CD90 APC-CD90
- CD105 APC-CD105
- the reaction was performed with CD146 (PE-CD146), CD271 (PE-CD271), and STRO-1 (FITC-STRO1) (all of which were BD Biosciences, San Jose, CA, USA) for 20 minutes. Thereafter, the cells after the reaction were washed with PBS, and the percentage of positive cells was measured with a flow cytometer.
- dedifferentiated adipocytes obtained from a cell fraction of less than 40 ⁇ m are more mesenchymal stem cells than dedifferentiated adipocytes obtained from a cell fraction of 40 ⁇ m or more and less than 100 ⁇ m. It was confirmed that the ratio of CD146 positive cells as a marker was about 1.5 to 2 times higher.
- Example 3 Method for producing mesenchymal cells Subcultured dedifferentiated adipocytes obtained from the cell fraction of less than 40 ⁇ m obtained in Example 2 and dedifferentiated adipocytes obtained from the cell fraction of 40 ⁇ m or more and less than 100 ⁇ m, Cells from the first passage were seeded at 1 ⁇ 10 4 in a 12-well plate, and when they became confluent, induction culture was performed in an osteoblast induction medium for 21 days.
- the composition of the differentiation-inducing medium (DIFFERENTIATION-INDUCING CULTURE MEDIUM (may be referred to as IM or Osteogenic medium in the drawing)) is the growth medium (Growth medium (may be indicated as GM in the drawing)) [DMEM, 10% (v / v) fetal bovine serum (FBS; 13B103, Sigma-Aldrich), 1% antibiotics] to 100 nM dexamethasone (Sigma-Aldrich), 10 mM b-glycerphosphine (Sigma-Aldrich-Sigma-Aldrich-Sigma-Aldrich-Sigma-Aldrich-Sigma-Aldrich-Sigma-Aldrich-Sigma-Albich-Sigma-Aldrich-Sigma-Albich Aldrich) is added. This osteoblast induction was evaluated by alkaline phosphatase activity, alizarin red S staining, and calcium quantitative test
- alkaline phosphatase activity The cells at 0, 3, 5, 7, 10, 14 days after the start of induction were collected, the protein amount was measured using Pierce BCA protein Assay Reagent Kit (Thermo Scientific, Rockford, IL, USA) and alkaline phosphatase Activity was measured. As a result, as shown in FIG. 7, dedifferentiated fat cells obtained from the cell fraction of less than 40 ⁇ m (FIG. 7, under 40 ⁇ m IM) were obtained from the cell fraction of 40 ⁇ m or more and less than 100 ⁇ m. Compared to (FIG. 7, 40-100 ⁇ m IM), alkaline phosphatase activity was significantly higher on days 3, 5, and 7 after the start of induction.
- the present invention it becomes possible to efficiently collect mature adipocytes without damaging the isolated mature adipocytes.
- a large amount of dedifferentiated adipocytes can be produced, so that they can be widely used as a cell source for regenerative medicine.
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Le problème abordé par cette invention est de pourvoir à un procédé d'isolement d'une cellule adipeuse mature d'un tissu adipeux à une efficacité élevée, et à la production d'une cellule adipeuse dédifférenciée à partir de la cellule adipeuse mature. La solution selon l'invention porte sur un procédé de production d'une cellule adipeuse dédifférenciée, ledit procédé impliquant l'étape (A) suivante : traiter un tissu adipeux avec 0,02 % p/v d'une collagénase pour isoler une cellule adipeuse mature.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016520701A JP5991687B2 (ja) | 2014-07-23 | 2015-06-29 | 脱分化脂肪細胞の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-149676 | 2014-07-23 | ||
JP2014149676 | 2014-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016013352A1 true WO2016013352A1 (fr) | 2016-01-28 |
Family
ID=55162887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/068658 WO2016013352A1 (fr) | 2014-07-23 | 2015-06-29 | Procédé de production d'une cellule adipeuse dédifférenciée |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5991687B2 (fr) |
WO (1) | WO2016013352A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105749347A (zh) * | 2016-02-24 | 2016-07-13 | 广州赛莱拉干细胞科技股份有限公司 | 一种美容填充物及其制备方法 |
JP2020066624A (ja) * | 2018-10-18 | 2020-04-30 | 学校法人日本大学 | 壊死性腸炎治療用組成物 |
WO2023190736A1 (fr) * | 2022-03-29 | 2023-10-05 | 学校法人日本大学 | Procédé de production de cellules adipeuses dédifférenciées humaines et milieu de culture pour la production de cellules adipeuses dédifférenciées humaines à partir de cellules adipeuses matures humaines |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7020667B2 (ja) * | 2017-12-11 | 2022-02-16 | 学校法人日本大学 | 哺乳動物由来の脱分化脂肪細胞から神経細胞を製造する方法及び哺乳動物由来の脱分化脂肪細胞から神経細胞への分化誘導用キット |
JP6826744B1 (ja) | 2020-07-17 | 2021-02-10 | 医療法人Yanaga CLinic | 成熟脂肪細胞含有組成物の製造方法 |
EP4431104A1 (fr) * | 2021-11-11 | 2024-09-18 | Keio University | Traitement de l'arthrose du genou en utilisant une lignée de cellules souches mésenchymateuses dérivées de tissu adipeux |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000157260A (ja) * | 1998-11-26 | 2000-06-13 | Toyobo Co Ltd | 初代前駆脂肪細胞の分化誘導方法及びその分化用培地 |
WO2008150001A1 (fr) * | 2007-06-08 | 2008-12-11 | Biomaster, Inc. | Amas adipeux |
WO2008153179A1 (fr) * | 2007-06-14 | 2008-12-18 | Akifumi Matsuyama | Cellule souche multipotentielle issue de tissu adipeux |
JP2010124814A (ja) * | 2008-12-01 | 2010-06-10 | Olympus Corp | 細胞分離装置およびコラゲナーゼ除去方法 |
JP2011116715A (ja) * | 2009-12-04 | 2011-06-16 | Josai Univ | 幹細胞増殖用組成物 |
JP2013017434A (ja) * | 2011-07-12 | 2013-01-31 | Kanazawa Univ | 神経細胞とグリア細胞を共培養する方法 |
JP2013223504A (ja) * | 2010-11-09 | 2013-10-31 | Otsuka Pharmaceut Factory Inc | 細胞生存率低下抑制剤 |
JP2014509517A (ja) * | 2011-03-18 | 2014-04-21 | アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) | 軟骨細胞分化培地および細胞の軟骨細胞分化を誘導するための方法 |
JP2014511827A (ja) * | 2011-03-15 | 2014-05-19 | セル・アイディアズ・ピーティーワイ・リミテッド | 医薬組成物およびその局所使用 |
-
2015
- 2015-06-29 JP JP2016520701A patent/JP5991687B2/ja not_active Expired - Fee Related
- 2015-06-29 WO PCT/JP2015/068658 patent/WO2016013352A1/fr active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000157260A (ja) * | 1998-11-26 | 2000-06-13 | Toyobo Co Ltd | 初代前駆脂肪細胞の分化誘導方法及びその分化用培地 |
WO2008150001A1 (fr) * | 2007-06-08 | 2008-12-11 | Biomaster, Inc. | Amas adipeux |
WO2008153179A1 (fr) * | 2007-06-14 | 2008-12-18 | Akifumi Matsuyama | Cellule souche multipotentielle issue de tissu adipeux |
JP2010124814A (ja) * | 2008-12-01 | 2010-06-10 | Olympus Corp | 細胞分離装置およびコラゲナーゼ除去方法 |
JP2011116715A (ja) * | 2009-12-04 | 2011-06-16 | Josai Univ | 幹細胞増殖用組成物 |
JP2013223504A (ja) * | 2010-11-09 | 2013-10-31 | Otsuka Pharmaceut Factory Inc | 細胞生存率低下抑制剤 |
JP2014511827A (ja) * | 2011-03-15 | 2014-05-19 | セル・アイディアズ・ピーティーワイ・リミテッド | 医薬組成物およびその局所使用 |
JP2014509517A (ja) * | 2011-03-18 | 2014-04-21 | アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) | 軟骨細胞分化培地および細胞の軟骨細胞分化を誘導するための方法 |
JP2013017434A (ja) * | 2011-07-12 | 2013-01-31 | Kanazawa Univ | 神経細胞とグリア細胞を共培養する方法 |
Non-Patent Citations (2)
Title |
---|
KEN YAGI ET AL.: "Seijuku Shibo Saibo Yurai no Zenku Shibo Saibokabu DFAT-D1 no Juritsu", JOURNAL OF JAPAN SOCIETY FOR THE STUDY OF OBESITY, vol. 11, no. 3, 2005, pages 92 - 94 * |
NIINA TSURUMACHI ET AL.: "Hito Hoho Shibotai kara Datsubunka Shibo Saibo o Kakutoku suru Koso Shori Joken no Kento", REGENERATIVE MEDICINE, vol. 14, no. 2015, February 2015 (2015-02-01), pages 219, O-23 - 5 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105749347A (zh) * | 2016-02-24 | 2016-07-13 | 广州赛莱拉干细胞科技股份有限公司 | 一种美容填充物及其制备方法 |
JP2020066624A (ja) * | 2018-10-18 | 2020-04-30 | 学校法人日本大学 | 壊死性腸炎治療用組成物 |
JP7348612B2 (ja) | 2018-10-18 | 2023-09-21 | 学校法人日本大学 | 壊死性腸炎治療用組成物 |
WO2023190736A1 (fr) * | 2022-03-29 | 2023-10-05 | 学校法人日本大学 | Procédé de production de cellules adipeuses dédifférenciées humaines et milieu de culture pour la production de cellules adipeuses dédifférenciées humaines à partir de cellules adipeuses matures humaines |
Also Published As
Publication number | Publication date |
---|---|
JP5991687B2 (ja) | 2016-09-14 |
JPWO2016013352A1 (ja) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5991687B2 (ja) | 脱分化脂肪細胞の製造方法 | |
Di Taranto et al. | Qualitative and quantitative differences of adipose-derived stromal cells from superficial and deep subcutaneous lipoaspirates: a matter of fat | |
Zhang et al. | Isolation, characterization and multi-lineage differentiation of stem cells from human exfoliated deciduous teeth | |
TWI338714B (en) | Method of isolation and enrichment of mesenchymal stem cells from amniotic fluid | |
Ponnaiyan et al. | Comparison of phenotype and differentiation marker gene expression profiles in human dental pulp and bone marrow mesenchymal stem cells | |
CN104630144B (zh) | 一种脐血间充质干细胞的分离及培养方法 | |
Tran et al. | Various methods for isolation of multipotent human periodontal ligament cells for regenerative medicine | |
CN111454893B (zh) | 一种无血清、无异源成分的间充质干细胞培养基及其应用 | |
WO2016049986A1 (fr) | Procédé de séparation de cellules souches mésenchymateuses de cordon ombilical | |
CN109136174B (zh) | 一种延缓衰老的干细胞来源外泌体制剂 | |
Khanna-Jain et al. | Growth and differentiation of human dental pulp stem cells maintained in fetal bovine serum, human serum and serum-free/xeno-free culture media | |
TWI523947B (zh) | 人類多能性類胚胎幹細胞先驅細胞 | |
Baghalishahi et al. | Cardiac extracellular matrix hydrogel together with or without inducer cocktail improves human adipose tissue-derived stem cells differentiation into cardiomyocyte–like cells | |
WO2012068710A1 (fr) | Procédés destinés à extraire une cellule souche mésenchymateuse d'une faible quantité de tissu adipeux humain et culture de masse de celle-ci | |
JP6494756B2 (ja) | 幹細胞培養のための培地組成物 | |
JP6781752B2 (ja) | 脂肪間質細胞を急速分離する組成物 | |
JP2024133719A (ja) | 振盪浮遊培養を用いた間葉系幹細胞の未分化性維持方法 | |
JP7064254B2 (ja) | ヒト臍帯から幹細胞を分離する方法 | |
CN105462917B (zh) | 一种牙周膜干细胞成脂分化诱导液及方法 | |
CN103184191A (zh) | 大鼠大网膜脂肪来源间充质干细胞的提取方法和专用培养基 | |
Zhao et al. | The effect of a human acellular amniotic membrane loaded with mechanical stretch-stimulated bone marrow mesenchymal stem cells for the treatment of pelvic floor dysfunction | |
JP4646600B2 (ja) | 間葉系幹細胞の培養方法 | |
Kadivar et al. | Isolation, culture and characterization of postnatal human umbilical vein-derived mesenchymal stem cells | |
CN101709291A (zh) | 一种基于vpa诱导的人骨髓间充质干细胞体外分化肝细胞的方法 | |
CN110964691B (zh) | 子宫内膜干细胞的定向成脂分化培养 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15825518 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016520701 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15825518 Country of ref document: EP Kind code of ref document: A1 |